Tier 4 — mechanistic

Evaluation of Urolithin A and Fisetin on Improving Sleep and Aging Biomarkers in Middle-Aged and Older Adults

Huazhong University of Science and Technology study team
ClinicalTrials.gov trial registry record 2025

Bibliography

Trial registry
View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
Funding
Lead sponsor: Huazhong University of Science and Technology; collaborator reported in public registry sources includes Abinopharm/Bonerge.
Competing interests
Registry records do not provide a manuscript-level conflict-of-interest statement.

Study snapshot

DesignRandomized quadruple-blind placebo-controlled four-arm trial.
ModelMiddle-aged and older adults with sleep disorder/aging-related outcomes.
SampleEnrollment reported as approximately 80-83 participants in current public registry sources.
InterventionFour arms: placebo, urolithin A 500 mg/day, fisetin 500 mg/day, or urolithin A 300 mg plus fisetin 200 mg/day, taken after breakfast for 12 weeks.
Duration12 weeks.
EndpointsSleep quality; Actigraphy and polysomnography; DNA methylation age; Inflammatory markers; Oxidative-stress markers; Circadian proteins; HOMA-IR; Gut microbiome and metabolite measures

What the study showed, in plain terms

This trial directly tests a daily fisetin arm and a urolithin A plus fisetin combination arm over 12 weeks, alongside urolithin A alone and placebo. It is one of the few registered studies of a longevity-supplement combination rather than fisetin alone.

The study is active but not recruiting in current registry summaries and has no posted outcome results. Until results are available, neither sleep improvement nor additive benefit from combining urolithin A and fisetin can be assumed.

Key findings

  • The fisetin-alone arm uses 500 mg/day for 12 weeks.
  • The combination arm uses 300 mg urolithin A plus 200 mg fisetin daily.
  • The design can eventually separate fisetin-alone, urolithin-A-alone and combination effects, but no results are posted yet.

What this study can and cannot tell us

  • Registry record only; no efficacy data are available.
  • Results will apply to the studied sleep/aging population and formulations, not to all supplement users.
  • Combination safety and efficacy cannot be inferred before outcomes are reported.

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology